Oracle Corporation (ORCL) failed to extend gains with the stock declining -0.82% or $-0.33 to close the day at $40.1 on active trading volume of 7.78M shares, compared to its three month average trading volume of 13.17M. The Redwood City California 94065 based company has been outperforming the application software group over the past 52 weeks, with the stock gaining 14.04%, compared to the industry which has advanced 26.96% over the same period. With RSI of 57.59, the stock should still continue to rise and get closer to its one year target estimate of $43.5, making it a hold for now.
Oracle Corporation develops, manufactures, markets, sells, hosts, and supports database and middleware software, application software, cloud infrastructure, hardware systems, and related services worldwide. It offers services in three primary layers of the cloud: Software as a Service, Platform as a Service, and Infrastructure as a Service. The company licenses its Oracle Database software, which enables storage, retrieval, and manipulation of various forms of data; and Oracle Fusion Middleware software to build, deploy, secure, access, and integrate business applications, as well as automate their business processes. It also provides a range of software for mobile computing to address the development needs of businesses; and Java, a software development language. In addition, the company offers application software, such as human capital and talent management, customer experience and customer relationship management, financial management and governance, risk and compliance, procurement, project portfolio management, supply chain management, business analytics and enterprise performance management, and industry-specific application software. Further, it offers hardware systems products, such as Oracle Engineered Systems, servers, storage, networking, industry specific hardware, virtualization software, operating systems, management software, and related hardware services. Additionally, the company offers customers with rights to software product upgrades and maintenance releases, patches released, and Internet access to technical content, as well as Internet and telephone access to technical support personnel. The company also provides consulting services, such as IT strategy alignment, enterprise architecture planning and design, initial product implementation and integration, and ongoing product enhancement and upgrade; customer support services; and education services. Oracle Corporation was founded in 1977 and is headquartered in Redwood City, California.
Cognizant Technology Solutions Corporation (CTSH) grew with the stock adding 0.5% or $0.26 to close at $52.76 on active trading volume of 7.76M compared its three months average trading volume of 6.42M. The Teaneck New Jersey 07666 based company operating under the Business Software & Services industry has been trending down for the last 52 weeks, with the shares price now -9.87% down for the period and down by -5.84% so far this year. With price target of $63.81 and a 16.11% rebound from 52-week low, Cognizant Technology Solutions Corporation has plenty of upside potential, making it a hold with a view buy.
Cognizant Technology Solutions Corporation provides information technology (IT), consulting, and business process services worldwide. The company operates through four segments: Financial Services, Healthcare, Manufacturing/Retail/Logistics, and Other. Its consulting and technology services include IT strategy consulting, program management consulting, operations improvement consulting, strategy consulting, and business consulting services; and application design and development, systems integration, enterprise resource planning, and customer relationship management implementation services. The company also offers enterprise information management services, such as strategic, advisory, and management consulting; enterprise data management; descriptive analytics/business intelligence; strategic corporate performance management; and packaged analytics services, as well as big data services that assist clients in managing and deriving actionable insights. In addition, it provides application testing services; and develops, licenses, implements, and supports proprietary and third-party software products, as well as offers digital technologies services. Further, the company offers outsourcing services, such as application maintenance services; IT infrastructure services; and business process services, including clinical data management, pharmacovigilance, equity research support, commercial operations, and order management. It serves various industries, including banking and insurance; healthcare and life sciences; manufacturing and logistics; retail, travel, and hospitality; consumer goods; communications; information, media, and entertainment; and technology. The company markets and sells services through its professional staff, senior management, and direct sales personnel. Cognizant Technology Solutions Corporation was founded in 1998 and is headquartered in Teaneck, New Jersey.
Gilead Sciences Inc. (GILD) continued its upward trend with the stock climbing 0.07% or $0.05 to close the day at $72.39 on lower than average trading volume of 7.5M shares, compared to its three month average trading volume of 9.69M. The Foster City California 94404 based company has been outperforming the biotechnology companies by 1.4954% for last three months and its recent gains have pushed the stock slightly up 1.09% YTD, versus the biotechnology industry which is down -5.25% for the same period. The RSI of 50.38 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.
Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.